Clinical Trial Update: Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 intravitreal safety study of REGN2176-3 in adults 50 years and older with wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• REGN2176-3

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Neovascular Wet Age-related Macular Degeneration (AMD) | Phase 1 | Status: COMPLETED